Recombinant factor VIII in the management of hemophilia A: current use and future promise

References

• AledortLMHistory of haemophiliaHaemophilia200713Suppl 51218240391
   PubMed Web of Science ®Google Scholar
• MannucciPMBack to the future: a recent history of haemophilia treatmentHaemophilia200814Suppl 3101818510516
   PubMed Web of Science ®Google Scholar
• LarssonSAWiechelBDeaths in Swedish hemophiliacs, 1957–1980Acta Med Scand198321431992066660026
   PubMedGoogle Scholar
• LjungRCIntracranial haemorrhage in haemophilia A and BBr J Haematol2008140437838418081890
   PubMed Web of Science ®Google Scholar
• DarbySCKanSWSpoonerRJMortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIVBlood2007110381582517446349
   PubMed Web of Science ®Google Scholar
• De MoerloosePUrbancikWVan Den BergHMRichardsMA survey of adherence to haemophilia therapy in six European countries: results and recommendationsHaemophilia200814593193818684125
   PubMed Web of Science ®Google Scholar
• IkkalatEHelskeGMyllylaHChanges in the life expectancy of patients with severe haemophilia A in Finland in 1930–79Br J Haematol1982527126810913
   PubMed Web of Science ®Google Scholar
• TriemstraMRosendaalFRSmitCVan der PloegHMBriëtEMortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986Ann Intern Med1995123118238277486463
   PubMed Web of Science ®Google Scholar
• SoucieJMNussREvattBMortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project InvestigatorsBlood200096243744210887103
   PubMed Web of Science ®Google Scholar
• PoonMCLukeKHHaemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activitiesHaemophilia200814587988818637966
   PubMed Web of Science ®Google Scholar
• PlugIVan Der BomJGPetersMMortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort studyJ Thromb Haemost20064351051616460432
   PubMed Web of Science ®Google Scholar
• StieltjesNCalvezTDemiguelVFrench ICH Study GroupIntracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for deathHaemophilia200511545245816128887
   PubMed Web of Science ®Google Scholar
• MishraPNaithaniRDolaiTIntracranial haemorrhage in patients with congenital haemostatic defectsHaemophilia200814595295518637845
   PubMed Web of Science ®Google Scholar
• GoedertJJChenBEPreissLAledortLMRosenbergPSReconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940–1990Am J Epidemiol2007165121443145317379617
   PubMed Web of Science ®Google Scholar
• BerntorpEArcheyWAuerswaldGA systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate -P: history and clinical performanceEur J Haematol Suppl20087033518380871
   PubMedGoogle Scholar
• BlanchetteVSShapiroADLiesnerRJrAHF-PFM Clinical Study GroupPlasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJ Thromb Haemost2008681319132618503631
   PubMed Web of Science ®Google Scholar
• MäkipernaaAvon BonsdorffLFifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrateHaemophilia200814361261418312362
   PubMed Web of Science ®Google Scholar
• Mauser-BunschotenEPPosthouwerDFischerKvan den BergHMSafety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-upHaemophilia200713669770017877729
   PubMed Web of Science ®Google Scholar
• BrookerMRegistry of clotting factor concentrates8th ed2008World Federation of Hemophilia. Available at: www.wfh.org
   Google Scholar
• NégrierCShapiroABerntorpESurgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patientsThromb Haemost2008100221722318690340
   PubMed Web of Science ®Google Scholar
• AshraniAAKeyNSSoucieJMDuffyNForsythAGeraghtySUniversal Data Collection Project InvestigatorsSeptic arthritis in males with haemophiliaHaemophilia200814349450318298584
   PubMed Web of Science ®Google Scholar
• NeunertCEMillerKLJourneycakeJMBuchananGRImplantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experienceHaemophilia200814226027018179577
   PubMed Web of Science ®Google Scholar
• JayandharanGRSrivastavaAThe phenotypic heterogeneity of severe hemophiliaSemin Thromb Hemost200834112814118393149
   PubMed Web of Science ®Google Scholar
• ShettySGhoshKReduced clinical severity in a mutationally well-characterized cohort of severe hemophilia with associated thrombophiliaAm J Clin Pathol20081301848718550475
   PubMed Web of Science ®Google Scholar
• BissTTChanAKBlanchetteVSIwenofuLNMcLimontMCarcaoMDAssociation of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC)The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis surveyHaemophilia200814592393018637844
   PubMed Web of Science ®Google Scholar
• RisebroughNOhPBlanchetteVCurtinJHitzlerJFeldmanBMCost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia AHaemophilia200814474375218422610
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMComparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practiceHaemophilia200713Suppl 24917685917
   PubMed Web of Science ®Google Scholar
• LöfqvistTNilssonIMBerntorpEPetterssonHHaemophilia prophylaxis in young patients – a long-term follow-upJ Intern Med199724153954009183307
   PubMed Web of Science ®Google Scholar
• MannucciPMNeed for randomized trials in hemophiliaJ Thromb Haemost20064350150216460428
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med2007357653554417687129
   PubMed Web of Science ®Google Scholar
• LjungRChambostHStainAMDiMicheleDHaemophilia in the first years of lifeHaemophilia200814Suppl 318819518510541
   PubMed Web of Science ®Google Scholar
• TraivareeCBlanchetteVArmstrongDFlorosGStainAMCarcaoMDIntracranial bleeding in haemophilia beyond the neonatal period – the role of CT imaging in suspected intracranial bleedingHaemophilia200713555255917880443
   PubMed Web of Science ®Google Scholar
• CollinsPWBlanchetteVSFischerKOn behalf of the rAHF-PFM study groupBreak-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia AJ Thromb Haemost20097341342019143924
   PubMed Web of Science ®Google Scholar
• GringeriAVon MackensenSQuality of life in haemophiliaHaemophilia200814Suppl 3192518510517
   PubMed Web of Science ®Google Scholar
• TagliaferriAFranchiniMCoppolaAEffects of secondary prophylaxis started in adolescent and adult haemophiliacsHaemophilia200814594595118540895
   PubMed Web of Science ®Google Scholar
• SchobessRKurnikKFriedrichsFEffects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort studyThromb Haemost2008991717618217137
   PubMed Web of Science ®Google Scholar
• StobartKIorioAWuJKClotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BCochrane Database Syst Rev2006Issue 2Art. No: CD003429. DOI:10.1002/14651858.CD003429.pub3.
   PubMed Web of Science ®Google Scholar
• JansenNWRoosendaalGLafeberFPUnderstanding haemophilic arthropathy: an exploration of current open issuesBr J Haematol2008143563264018950457
   PubMed Web of Science ®Google Scholar
• LobetSPendevilleEDalzellRThe role of physiotherapy after total knee arthroplasty in patients with haemophiliaHaemophilia200814598999818582230
   PubMed Web of Science ®Google Scholar
• Rodriguez-MerchanECAnkle surgery in haemophilia with special emphasis on arthroscopic debridementHaemophilia200814591391918637842
   PubMed Web of Science ®Google Scholar
• TatsunamiSMimayaJShirahataACurrent status of Japanese HIV-infected patients with coagulation disorders: coinfection with both HIV and HCVInt J Hematol200888330431018677450
   PubMed Web of Science ®Google Scholar
• RentzAFloodEAltisentCMembers of the HAEMO-QoL-A Steering CommitteeCross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophiliaHaemophilia20081451023103418665853
   PubMed Web of Science ®Google Scholar
• ShapiroADKorth-BradleyJPoonMCUse of pharmacokinetics in the coagulation factor treatment of patients with haemophiliaHaemophilia200511657158216236106
   PubMed Web of Science ®Google Scholar
• ButenasSParhami-SerenBGisselMTGompertsEDFassDNMannKGPotency and mass of factor VIII in FVIII productsHaemo‐philia20091516372
   PubMed Web of Science ®Google Scholar
• LentingPJChristopheODGuéguenPThe disappearing act of factor VIIIHaemophilia200891[Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• FischerKValentinoLLjungRBlanchetteVProphylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitorsHaemophilia200814Suppl 319620118510542
   PubMed Web of Science ®Google Scholar
• LewisSJStephensEFlorouGMeasurement of global haemostasis in severe haemophilia A following factor VIII infusionBr J Haematol2007138677578217672884
   PubMed Web of Science ®Google Scholar
• DiMicheleDImmune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approachJ Thromb Haemost20075Suppl 114315017635720
   PubMed Web of Science ®Google Scholar
• OldenburgJPavlovaAGenetic risk factors for inhibitors to factors VIII and IXHaemophilia200612Suppl 6152217123389
   PubMed Web of Science ®Google Scholar
• BoekhorstJLariGRD’OironRFactor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutationsHaemophilia200814472973518503540
   PubMed Web of Science ®Google Scholar
• BerntorpEDifferential response to bypassing agents complicates treatment in patients with haemophilia and inhibitorsHaemophilia200915131019016901
   PubMed Web of Science ®Google Scholar
• Jiménez-YusteVAlvarezMTMartín-SalcesMProphylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situationsHaemophilia200915120320919149850
   PubMed Web of Science ®Google Scholar
• TeitelJMCarcaoMLillicrapDOrthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative careHaemophilia200915122723918752535
   PubMed Web of Science ®Google Scholar
• MargaglioneMCastamanGMorfiniMAICE-Genetics Study GroupThe Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotypeHaematologica200893572272818387975
   PubMed Web of Science ®Google Scholar
• GreningerDASaint-RemyJMJacqueminMBenhidaADiMicheleDMThe use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profileHaemophilia200814229530218081826
   PubMed Web of Science ®Google Scholar
• GringeriAMussoRMazzucconiMGRITS-FITNHES Study GroupImmune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor responseHaemophilia200713437337917610550
   PubMed Web of Science ®Google Scholar
• GreenPMBagnallRDWaseemNHGiannelliFHaemophilia A mutations in the UK: results of screening one-third of the populationBr J Haematol2008143111512818691168
   PubMed Web of Science ®Google Scholar
• CalvezTLaurianYGoudemandJInhibitor incidence with recombinant vs plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studiesJ Thromb Haemost2008639039218036187
   PubMed Web of Science ®Google Scholar
• GouwSCvan der BomJGMarijke van den BergHTreatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort studyBlood2007109114648465417289808
   PubMed Web of Science ®Google Scholar
• Lacroix-DesmazesSNavarreteAMAndréSBayryJKaveriSVDasguptaSDynamics of factor VIII interactions determine its immunologic fate in hemophilia ABlood2008112224024918469198
   PubMed Web of Science ®Google Scholar
• KreuzWThe role of VWF for the success of immune tolerance inductionThromb Res2008122Suppl 2S7S1218549910
   PubMed Web of Science ®Google Scholar
• FedericiABMannucciPMMarcoPVon Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting reportHaemophilia200814113313917941830
   PubMedGoogle Scholar
• ter AvestPCFischerKMancusoMECANAL Study GroupRisk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practiceJ Thromb Haemost20086122048205418983511
   PubMed Web of Science ®Google Scholar
• MussoRSantagostinoEFaradjiAKOGENATE Bayer European PMS Study GroupSafety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical settingThromb Haemost2008991525818217134
   PubMed Web of Science ®Google Scholar
• ShapiroADAnti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia AVasc Health Risk Manag20073555556518078007
   PubMedGoogle Scholar
• SingletonESmithJKavanaghMNolanBWhiteBLow risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIIIThromb Haemost20079861188119218064312
   PubMed Web of Science ®Google Scholar
• WilsonKRickettsMNA third episode of transfusion-derived vCJDLancet200636895522037203917161714
   PubMed Web of Science ®Google Scholar
• KesslerCMGillJCWhiteGC2ndB-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover studyHaemophilia2005112849115810908
   PubMed Web of Science ®Google Scholar
• GruppoRABrownDWilkesMMNavickisRJComparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis – a meta-analysisHaemophilia20039325126012694514
   PubMed Web of Science ®Google Scholar
• GruppoRABrownDWilkesMMNavickisRJIncreased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII – a robust meta-analytic findingHaemophilia200410544945115357769
   PubMed Web of Science ®Google Scholar
• Di PaolaJSmithMPKlamrothRMannucciPMKollmerCFeingoldJKesslerCPollmannHMorfiniMUdataCRothschildCHermansCJancoRReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia AHaemophilia200713212413017286764
   PubMed Web of Science ®Google Scholar
• FranchiniMTagliaferriAMannucciPMThe management of hemophilia in elderly patientsClin Interv Aging20072336136818044186
   PubMed Web of Science ®Google Scholar
• DolanGHermansCKlamrothRMadhokRSchutgensRESpenglerUChallenges and controversies in haemophilia care in adulthoodHaemophilia200915Suppl 1202719125937
   PubMed Web of Science ®Google Scholar
• TuinenburgAMauser-BunschotenEPVerhaarMCBiesmaDHSchutgensRECardiovascular disease in patients with haemophiliaJ Thromb Haemost20081018[Epub ahead of print].
   PubMedGoogle Scholar
• KulkarniRSoucieJMEvattBLHemophilia Surveillance System Project InvestigatorsPrevalence and risk factors for heart disease among males with hemophiliaAm J Hematol2005791364215849761
   PubMed Web of Science ®Google Scholar
• WalshCEAdult Prophylaxis Study GroupProphylaxis for adults with severe haemophilia: a compelling need for evidence-based guidelinesHaemophilia200814238538618201188
   PubMed Web of Science ®Google Scholar
• LillicrapDExtending half-life in coagulation factors: where do we stand?Thromb Res2008122Suppl 4S2S818929522
   PubMed Web of Science ®Google Scholar
• PowellJSLiposomal approach towards the development of a longer-acting factor VIIIHaemophilia200713Suppl 2232817685920
   PubMed Web of Science ®Google Scholar
• PowellJSNugentDJHarrisonJASoniALukAStassHGorinaESafety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia AJ Thromb Haemost20086227728318039351
   PubMed Web of Science ®Google Scholar
• MartinowitzULalezariSLuboshitzJLubetskyASpiraJInfusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia AHaemophilia20081451122112418564190
   PubMed Web of Science ®Google Scholar
• SpiraJPlyushchOPAndreevaTAAndreevYProlonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomesBlood2006108123668367316888098
   PubMed Web of Science ®Google Scholar
• SpiraJPlyushchOPAndreevaTAKhametovaRNEvaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia AThromb Haemost2008100342943418766258
   PubMed Web of Science ®Google Scholar
• KasudaSKuboASakuraiYEstablishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia AJ Thromb Haemost2008681352135918485084
   PubMed Web of Science ®Google Scholar
• MurphySLHighKAGene therapy for haemophiliaBr J Haematol2008140547948718275425
   PubMed Web of Science ®Google Scholar
• OhmoriTIshiwataAKashiwakuraYPhenotypic correction of hemophilia A by ectopic expression of activated factor VII in plateletsMol Ther20081681359136518523449
   PubMed Web of Science ®Google Scholar
• PrasadSLillicrapDLabelleAEfficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia ABlood2008111267267917978172
   PubMed Web of Science ®Google Scholar
• OldenburgJDolanGLemmGHaemophilia care then, now and in the futureHaemophilia200915Suppl 12719125934
   PubMed Web of Science ®Google Scholar
• PipeSWValentinoLAOptimizing outcomes for patients with severe haemophilia AHaemophilia200713Suppl 4116
   Web of Science ®Google Scholar
• PowellJThe next generation of anti-haemophilia factor, factor VIII. Long-lasting protection from spontaneous bleeding, are we there yet?Thromb Haemost2008100336536618766246
   PubMed Web of Science ®Google Scholar